Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer. Kakiuchi Y, Saruwatari K, Tokito T, Iriki T, et al. Lung Cancer 2025;204:108578.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kakiuchi Y, Saruwatari K, Tokito T, Iriki T, et al. Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer. Lung Cancer 2025;204:108578.
PMID: 40349417